You may also report side effects at https://www.fda.gov/medwatch. Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. If used, monitor more closely for evidence of bleeding. Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.Repaglinide: Clopidogrel may increase the serum concentration of Repaglinide. Management: Avoid combination when possible. Talk with the doctor.• Bleeding like vomiting blood or vomit that looks like coffee grounds; coughing up blood; blood in the urine; black, red, or tarry stools; bleeding from the gums; abnormal vaginal bleeding; bruises without a reason or that get bigger; or any severe or persistent bleeding.• Low blood sugar like dizziness, headache, fatigue, feeling weak, shaking, fast heartbeat, confusion, increased hunger, or sweating.• Thrombotic thrombocytopenic purpura like confusion, severe fatigue, severe weakness, weakness on one side of body, trouble speaking, trouble thinking, balance changes, drooping on one side of face, vision changes, fast heartbeat, fever, headache, pale skin, unable to pass urine, blood in the urine, purple spots on skin or mouth, seizures, severe diarrhea, abdominal pain, nausea, vomiting, dyspnea, or yellow skin.• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. help if you have any side effects that bother you or do not go away. Morphine (Systemic) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). Management: Avoid administration of clopidogrel until cangrelor infusion is discontinued.Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. More severe side effects include bleeding and thrombotic If combined, consider dose reduction of the BCRP inhibitor and separation in the timing of administration.Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). In this trial, aspirin in combination with clopidogrel was used for patients who underwent carotid artery stenting, which suggests that this antiplatelet combination is effective Data from prospective, randomized, double-blind, placebo-controlled trials support the use of clopidogrel as part of the antiplatelet regimen for percutaneous coronary intervention (PCI) Data from a prospective, randomized, double-blind, placebo-controlled trial in patients with a history of atherosclerotic cardiovascular disease support the long-term use of clopidogrel for secondary prevention of cardiovascular events (eg, ischemic stroke, myocardial infarction, vascular death) Data from multiple clinical trials support the use of clopidogrel in combination with aspirin as an antithrombotic strategy for transcatheter aortic valve replacement (TAVR) Data from a limited number of patients in one clinical trial suggest that clopidogrel may be an effective component of the thromboprophylaxis regimen for transcatheter mitral valve repair when using the MitraClip device Hypersensitivity (eg, anaphylaxis) to clopidogrel or any component of the formulation; active pathological bleeding (eg, peptic ulcer, intracranial hemorrhage).• Bare metal stent implantation: DAPT for a minimum of 1 month (ACC/AHA [Levine 2016]). Duration of therapy, in general, is determined by the type of stent placed (bare metal or drug eluting) and whether an acute coronary syndrome event was ongoing at the time of placement (ACC/AHA [Levine 2016]; AHA/ACC/SCAI/ACS/ADA [Grines 2007]).Signs of bleeding; hemoglobin and hematocrit periodically.Information related to use during pregnancy is limited (Bauer 2012; De Santis 2011; Myers 2011). Consult drug interactions database for more detailed information.• Lower GI bleed patients: An individualized and multidisciplinary approach should be utilized to determine therapy discontinuation and management in patients with acute lower GI bleed (LGIB) who are on antiplatelet medications; risk of ongoing bleeding should be weighed with risk of thromboembolic events. Follow all instructions closely. (Moderate) Although aspirin may be used in combination with clopidogrel, both drugs are associated with bleeding. Ritonavir may decrease serum concentrations of the active metabolite(s) of Clopidogrel.Rivaroxaban: Antiplatelet Agents (P2Y12 Inhibitors) may enhance the adverse/toxic effect of Rivaroxaban. Treprostinil: CYP2C8 Inhibitors (Moderate) may increase the serum concentration of Treprostinil. Plavix (clopidogrel bisulfate) is a thienopyridine class of drug that inhibits platelet aggregation and thus inhibits aspects of blood clotting used to treat patients with acute coronary syndrome, myocardial infarction (MI), peripheral vascular disease and some stroke (ischemic type) patients. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs.Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid.